JP5225288B2 - キナーゼ阻害剤として有用なチアゾリル化合物 - Google Patents

キナーゼ阻害剤として有用なチアゾリル化合物 Download PDF

Info

Publication number
JP5225288B2
JP5225288B2 JP2009543183A JP2009543183A JP5225288B2 JP 5225288 B2 JP5225288 B2 JP 5225288B2 JP 2009543183 A JP2009543183 A JP 2009543183A JP 2009543183 A JP2009543183 A JP 2009543183A JP 5225288 B2 JP5225288 B2 JP 5225288B2
Authority
JP
Japan
Prior art keywords
substituted
alkyl
mmol
aryl
amino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2009543183A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010514686A5 (enExample
JP2010514686A (ja
Inventor
アンヌ・マリニエ
クロード・ケスネル
マルコ・ドディエ
ステファン・ロワ
パトリス・ジル
マーク・ディ・ウィットマン
デイビッド・アール・ラングレー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of JP2010514686A publication Critical patent/JP2010514686A/ja
Publication of JP2010514686A5 publication Critical patent/JP2010514686A5/ja
Application granted granted Critical
Publication of JP5225288B2 publication Critical patent/JP5225288B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
JP2009543183A 2006-12-20 2007-12-19 キナーゼ阻害剤として有用なチアゾリル化合物 Expired - Fee Related JP5225288B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US87087206P 2006-12-20 2006-12-20
US60/870,872 2006-12-20
PCT/US2007/088124 WO2008079873A2 (en) 2006-12-20 2007-12-19 Thiazolyl compounds useful as kinase inhibitors

Publications (3)

Publication Number Publication Date
JP2010514686A JP2010514686A (ja) 2010-05-06
JP2010514686A5 JP2010514686A5 (enExample) 2011-07-28
JP5225288B2 true JP5225288B2 (ja) 2013-07-03

Family

ID=39563189

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009543183A Expired - Fee Related JP5225288B2 (ja) 2006-12-20 2007-12-19 キナーゼ阻害剤として有用なチアゾリル化合物

Country Status (6)

Country Link
US (1) US8148400B2 (enExample)
EP (1) EP2099794B1 (enExample)
JP (1) JP5225288B2 (enExample)
CN (1) CN101652363B (enExample)
NO (1) NO20092035L (enExample)
WO (1) WO2008079873A2 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008124757A1 (en) * 2007-04-10 2008-10-16 Bristol-Myers Squibb Company Thiazolyl compounds useful as kinase inhibitors
WO2008144345A2 (en) 2007-05-17 2008-11-27 Bristol-Myers Squibb Company Biomarkers and methods for determining sensitivity to insulin growth factor-1 receptor modulators
AU2010343102B2 (en) 2009-12-29 2016-03-24 Dana-Farber Cancer Institute, Inc. Type II Raf kinase inhibitors
CN102070518B (zh) * 2011-01-24 2012-05-02 江苏先声药物研究有限公司 取代吡啶及氮杂吲哚衍生物的合成
AU2015240518A1 (en) * 2014-04-05 2016-10-20 Syros Pharmaceuticals, Inc. Inhibitors of cyclin-dependent kinase 7 (CDK7)
CA2972239A1 (en) 2014-12-23 2016-06-30 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 (cdk7)
CN107427521B (zh) 2015-03-27 2021-08-03 达纳-法伯癌症研究所股份有限公司 细胞周期蛋白依赖性激酶的抑制剂
EP4019515A1 (en) 2015-09-09 2022-06-29 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinases
CN106932502B (zh) * 2015-12-31 2021-05-18 上海奥博生物医药股份有限公司 一种索拉菲尼中4-氯-2-吡啶甲酸甲酯含量的测定方法
CN107043375B (zh) * 2017-04-28 2020-03-20 江苏食品药品职业技术学院 一种制备达沙替尼及其中间体的新方法
JP7590185B2 (ja) 2018-06-25 2024-11-26 ダナ－ファーバー キャンサー インスティテュート， インコーポレイテッド Ｔａｉｒｅファミリーキナーゼインヒビターおよびそれらの使用
KR102253652B1 (ko) * 2019-08-19 2021-05-18 주식회사 셀젠텍 신규한 암전이 억제 활성을 갖는 화합물, 이의 제조방법 및 상기 화합물을 포함하는 암 전이 및 침윤 억제, 또는 암 치료용 약학적 조성물

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2257461T3 (es) * 2000-12-21 2006-08-01 Bristol-Myers Squibb Company Inhibidores de tiazolilo de tirosina quinasas de la familia tec.
US7169771B2 (en) * 2003-02-06 2007-01-30 Bristol-Myers Squibb Company Thiazolyl-based compounds useful as kinase inhibitors
WO2008124757A1 (en) * 2007-04-10 2008-10-16 Bristol-Myers Squibb Company Thiazolyl compounds useful as kinase inhibitors

Also Published As

Publication number Publication date
EP2099794A2 (en) 2009-09-16
CN101652363B (zh) 2013-04-17
JP2010514686A (ja) 2010-05-06
CN101652363A (zh) 2010-02-17
US20100048581A1 (en) 2010-02-25
NO20092035L (no) 2009-07-15
WO2008079873A2 (en) 2008-07-03
US8148400B2 (en) 2012-04-03
EP2099794B1 (en) 2013-05-15
WO2008079873A3 (en) 2008-10-02

Similar Documents

Publication Publication Date Title
JP5225288B2 (ja) キナーゼ阻害剤として有用なチアゾリル化合物
EP2049542B1 (en) Pyrrolotriazine kinase inhibitors
US8389527B2 (en) Substituted imidazopyridazines useful as kinase inhibitors
US7531539B2 (en) Pyrrolotriazine kinase inhibitors
JP5244118B2 (ja) 新規キナーゼ阻害剤
US7514435B2 (en) Pyrrolotriazine kinase inhibitors
JP6267231B2 (ja) カゼインキナーゼ１δ／ε阻害剤としての新規な置換イミダゾール
JP5385895B2 (ja) キナーゼ阻害剤として有用なチアゾリル化合物
CN104837844B (zh) 作为酪蛋白激酶1 d/e抑制剂的吡唑取代的咪唑并哌嗪
US7442700B2 (en) Pyrrolotriazine compounds useful as kinase inhibitors and methods of treating kinase-associated conditions therewith
JP5286281B2 (ja) アミノピラゾールキナーゼ阻害剤

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100715

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20100715

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20121016

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130115

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20130212

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20130312

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20160322

Year of fee payment: 3

LAPS Cancellation because of no payment of annual fees